NBY vs. MRKR, NEUP, CTXR, LPTX, ALVR, NXTC, LIXT, TXMD, IXHL, and ERNA
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Marker Therapeutics (MRKR), Neuphoria Therapeutics (NEUP), Citius Pharmaceuticals (CTXR), Leap Therapeutics (LPTX), AlloVir (ALVR), NextCure (NXTC), Lixte Biotechnology (LIXT), TherapeuticsMD (TXMD), Incannex Healthcare (IXHL), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs. Its Competitors
Marker Therapeutics (NASDAQ:MRKR) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.
Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 7.8% of Marker Therapeutics shares are owned by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
NovaBay Pharmaceuticals has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, NovaBay Pharmaceuticals had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for NovaBay Pharmaceuticals and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.67 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.
NovaBay Pharmaceuticals has a net margin of -102.72% compared to Marker Therapeutics' net margin of -271.12%. Marker Therapeutics' return on equity of -114.59% beat NovaBay Pharmaceuticals' return on equity.
Marker Therapeutics currently has a consensus target price of $13.17, suggesting a potential upside of 916.73%. NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential downside of 9.29%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than NovaBay Pharmaceuticals.
Summary
Marker Therapeutics beats NovaBay Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access